CN Patent

CN121844046A — 用于递送肠促胰岛素剂的rna组合物

Assigned to Individual · Expires 2026-04-10 · 0y expired

What this patent protects

本公开提供用于递送肠促胰岛素剂的组合物(例如，药物组合物)和相关技术(例如，其组分和/或与其相关的方法)。本公开尤其提供使用编码肠促胰岛素剂的多核糖核苷酸用于各种疾病的治疗方法。

USPTO Abstract

本公开提供用于递送肠促胰岛素剂的组合物(例如，药物组合物)和相关技术(例如，其组分和/或与其相关的方法)。本公开尤其提供使用编码肠促胰岛素剂的多核糖核苷酸用于各种疾病的治疗方法。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: CN121844046A
Jurisdiction: CN
Classification: —
Expires: 2026-04-10
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.